Daewon Pharmaceutical Co Ltd

Daewon Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.76, indicating a moderate reliance on debt financing, and a current ratio of 1.19, suggesting limited short-term liquidity cushion. The company’s free cash flow is negative at -27.04 billion KRW, while operating cash flow is positive at 42.31 billion KRW, highlighting a mismatch between operating performance and capital spending. The company’s profitability metrics are weak, with a return on equity of -0.52% and a return on assets of -0.22%, both significantly below the typical thresholds for pharmaceutical firms. This underperformance is exacerbated by a net loss of 1.38 billion KRW, despite a gross profit of 27.28 billion KRW, indicating high operating and non-operating expenses. Revenue is distributed across four segments: Pharmaceuticals, Cosmetics, Health Functional Food, and Other. The Pharmaceuticals segment is the core business, but the company’s exposure to cosmetics and health functional foods suggests diversification into consumer goods. However, the financial data does not provide segment-specific revenue figures, making it difficult to assess concentration risk. The company’s growth trajectory is uncertain, with no specific revenue growth rates provided in the input data. Analysts have assigned a mean price target of 15,250 KRW and a median of 16,000 KRW, with a mean recommendation of 1.60 (leaning toward buy). However, the absence of forward-looking guidance and the current net loss raise concerns about near-term performance. Risk factors include a negative net cash position after subtracting total debt, which signals liquidity risk. The company’s dilution risk is assessed as low, but the negative free cash flow and high capital expenditures (-42.13 billion KRW) suggest potential pressure to raise additional capital in the future. Recent events include the publication of the latest financial snapshot, which reveals a net loss and negative free cash flow. No specific filings or transcripts are cited in the input data, so the narrative is based on the most recent financial figures.